Dialysis(peritoneal dialysis and hemodialysis)
Conditions
Interventions
Henagliflozin group:Patients are given oral henagliflozin 5mg qd. If the patient cannot tolerate the dose, reduce to 2.5mg qd.
Placebo group:Patients are given oral placebo 5mg qd. If the patient cannot tolerate the dose, reduce to 0.5 tablets qd.
Sponsors
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Agree to join the study and sign the informed consent form. 2. 18-80 years old. 3. Hemodialysis patients with regular hemodialysis (including HD, HDF, HP) for more than 3 months. 4. Kt/V > 1.1 or UUR > 60% in a single hemodialysis within 3 months. 5. Peritoneal dialysis patients with regular CAPD, DAPD or APD for more than 3 months. 6. Kt/V =1.7 within 3 months in peritoneal dialysis patients. 7. Reach the diagnostic criteria of HFpEF [with symptoms of heart failure combined with one of the following: a) BNP > 300pg/ml or NT-proBNP > 8000pg / ml; b) left ventricular hypertrophy within 12 months (male > 110g/m2, female > 90g/m2); c) hospitalized due to heart failure within 1 year], and EF = 50%. 8. Patients with stable capacity load, and the BCM detection OH = 3.0. 9. The dose of anti-heart failure drugs (including RAS blocker, MRA, ß-blocker) is stable at least 4 weeks.
Exclusion criteria
Exclusion criteria: 1. Hypoglycemia occurs more than twice within 4 weeks. 2. Evidence of ketoacidosis within 3 months. 3. Patients with type 1 diabetes mellitus. 4. Hemoglobin 3.0). 8. Patients with systemic active infection. 9. Patients with uncured tumor. 10. Patients with symptoms of active genitourinary system infection. 11. Patients with history of cardiac valve replacement or repair operation. 12. Patients with history of persistent atrial fibrillation. 13. Patients allergic to henagliflozin. 14. Pregnant and lactating women. 15. Patients participating in other intervention studies. 16. Other conditions in which the investigators judge that the patient is not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular mass index, LVMI; | — |
Secondary
| Measure | Time frame |
|---|---|
| E/e’;NT-proBNP; | — |
Countries
China
Contacts
Public ContactGu Leyi
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed